Rapport Therapeutics CEO Ceesay Abraham Sells 8,210 Shares

What Happened

• Ceesay Abraham, CEO of Rapport Therapeutics (RAPP), sold a total of 8,210 shares on 2026-09-08 in two open‑market transactions. The larger sale was 7,141 shares at a weighted average price of $45.55 for $325,308; the smaller was 1,069 shares at a weighted average price of $46.01 for $49,190. Total proceeds reported: $374,498. These were sales (not purchases).

Key Details

• Transaction dates: 2026-09-08 (reported on Form 4 filed 2026-09-09 — timely with respect to the Form 4 deadline).
• Prices:
  • 7,141 shares — weighted avg $45.55; actual trade prices ranged $44.94–$45.90 (footnote F2).
  • 1,069 shares — weighted avg $46.01; actual trade prices ranged $45.95–$46.17 (footnote F3).
• Total shares sold: 8,210; total proceeds: $374,498.
• Shares owned after the transaction: not specified in the excerpt of the filing.
• Notable footnotes: trades were effected under a Rule 10b5-1 trading plan adopted March 27, 2026 (footnote F1). The filer offers to provide a per-price breakdown on request (F2, F3).

Context

• These were scheduled sales under a 10b5-1 plan, which typically allows insiders to sell pre-arranged amounts irrespective of short‑term company news. Sales are often routine and do not necessarily signal management views on company prospects. No options were exercised and no grants or gifts were reported in this filing.